3 major articles in the sub-journal to analyze the current situation and future of microbiome therapy

author:Warm-hearted research institute
3 major articles in the sub-journal to analyze the current situation and future of microbiome therapy
3 major articles in the sub-journal to analyze the current situation and future of microbiome therapy

Topics in this issue: Microbiome Therapy, IBD, Microfluidics, Microbiota-Disease Association, Risk Prediction, Sedentary, Gastrointestinal Diseases, Drug Discovery, Cardiovascular, Probiotics, Novo Nordisk, Capecitabine Tablets, Shanghai Pharmaceutical, Puluo Pharmaceutical

The daily newspaper was published by R. AI-assisted creation generation, manual review and proofreading.

Lancet: Artificial Microbiome Therapy: A New Perspective for Microbiome Therapy (Review)

Lancet Gastroenterology & Hepatology——[35.7]

(1) Modulation of intestinal microbiota has promise in the treatment of infectious and non-infectious chronic diseases;(2) Common methods of intestinal microbiota regulation include probiotics, prebiotics, synbiotics and fecal bacteria transplantation, among which fecal bacteria transplantation is effective in the treatment of recurrent Clostridium difficile infection (rCDI) and other diseases, but these methods have limitations in terms of precision, regulation, safety, reproducibility and targeting;(3) Emerging artificial microbiome therapies mainly include microbiota complexes (well-defined synthetic communities of fecal bacteria derivatives or strains, with a small number of products approved for the prevention of rCDI), bacteriophages, bacterial metabolites (e.g., short-chain fatty acids), engineered probiotics (as therapeutic vehicles) ;(4) These therapies are designed to provide consistent, targeted, and safe therapeutic products that improve rCDI by modulating the gut microbiota at different levels of precision and mechanism, inflammatory bowel disease, cancer, For the treatment of diseases such as diabetes, some R&D is already in the clinical trial stage, and (5) artificial microbiome therapies face challenges such as cost and lack of data.

【Original Information】

Fine-tuning the gut ecosystem: the current landscape and outlook of artificial microbiome therapeutics

2024-05-01, doi: 10.1016/s2468-1253(23)00357-6


Lancet Gastroenterology & Hepatology——[35.7]

(1) Microbiota therapy is a new direction in the treatment of inflammatory bowel disease (IBD), and this review summarizes the research status and challenges of IBD microbiota therapy, including fecal microbiota transplantation (FMT) and treatment with well-defined microbiota composition and composition, (2) the route of administration in IBD microbiota therapy includes nasogastric tube, oral capsule, enema and colonoscopy, (3) in 5 phase 2 randomized controlled trials (RCTs), more than 300 patients with mild to moderate ulcerative colitis were treated with FMT, 30.7% (9.6% in the placebo group), two preliminary RCTs showed promise for FMT in the treatment of Crohn's disease;(4) these trials provided valuable experience in antibiotic pretreatment, routes of administration to induce and maintain remission, therapeutic dose, number of donors, tracking of receptor colony implantation at the strain level, and (5) microbiota therapy is expected to be complementary or combined with existing therapies.

【Original Information】

Microbiota therapeutics for inflammatory bowel disease: the way forward

2024-05-01, doi: 10.1016/s2468-1253(23)00441-7

Nature: Leveraging Microbiota Characteristics and Trade-off Strategies to Enhance Microbiome Therapy (Perspectives)

Nature Reviews Bioengineering——[0]

(1) this article explores how to use the characteristics of the gut microbiome and its trade-offs to design effective microbiome therapeutics, (2) the gut microbiota has evolved a variety of survival strategies to adapt to changes and challenges in the gut environment (e.g., periodic supply of nutrients and host competition), (3) there are trade-offs in the survival strategies of microbes, such as rapid growth and resource efficiency and environmental adaptability, which limit the existence of so-called "superbacteria"; (4) Mathematical models can help optimize the performance of therapeutic microbiomes, but need to consider the flexible strategies and trade-offs of microbes;(5) A better understanding of the survival strategies and mechanisms of gut microbes can guide the design of more effective microbiome interventions.

【Original Information】

Exploiting gut microbial traits and trade-offs in microbiome-based therapeutics

2024-04-04, doi: 10.1038/s44222-024-00178-1

Fudan team: Microfluidic technology helps intestinal microbial therapy


(1) Luoran Shang's team at Fudan University developed a hydrogel microsphere with colon-targeting and mucosal adhesion capabilities as a multifunctional delivery platform for co-delivery of probiotics and helper molecules to achieve synergistic therapeutic efficacy;(2) The drug delivery system is based on microfluidic technology, with simple preparation process and controllable mode;(3) Multifunctional microspheres can significantly reduce enteritis, repair intestinal barrier function, enhance the colonization of probiotics in the intestine, and regulate the disordered intestinal flora;(4) In a mouse model of colitis, multifunctional microspheres have enhanced therapeutic effects;(5) This study reveals that intelligent droplet microspheres based on microfluidics can provide a versatile platform for advanced microbial therapies.

【Original Information】

Microfluidic-based multifunctional microspheres for enhanced oral co-delivery of probiotics and postbiotics

2024-04-03 , doi: 10.1016/j.biomaterials.2024.122564

MintTea: An integrated multi-omics approach to explore the association between gut microbiota and disease

Nature Communications——[16.6]

(1) the successful integration of multi-omics data for revealing disease-related microbiome modules through the introduction of the "MintTea" method;(2) the combination of canonical correlation analysis extensions, consensus analysis, and evaluation protocols in "MintTea" was able to identify multi-omics modules that were synergistically changing at multiple omics levels and were collectively associated with disease;(3) a module containing serum glutamate, TCA circulation-related metabolites, and bacterial species associated with insulin resistance was identified in the metabolic syndrome research sample;(4) Identification of a module associated with advanced colorectal cancer, including Peptic Streptococcus and Twin spp., and fecal amino acids, consistent with the metabolic activity of these species and their gradual increase in cancer development.

【Original Information】

Multi-omic integration of microbiome data for identifying disease-associated modules

2024-03-23, doi: 10.1038/s41467-024-46888-3

Nature: Combining genetics and gut microbiota to predict the risk of common diseases

Nature Aging——[16.6]

(1) This study demonstrated that the combination of polygenic genetic risk scores (PRSs) and gut microbiome scores can significantly improve the accuracy of risk prediction of common diseases;(2) PRSs outperformed traditional risk factors in predicting coronary artery disease (CAD), type 2 diabetes mellitus (T2D), Alzheimer's disease, and prostate cancer;(3) gut microbiome scores were improved in predicting CAD, T2D, and prostate cancer compared to age-based models alone;(4) PRSs, The comprehensive risk model combining gut microbiome scores with traditional risk factors has higher predictive performance than models based on traditional risk factors alone in all diseases studied;(5) The risk assessment model that integrates genetic and gut microbiome provides a new perspective for early detection and risk assessment of common chronic diseases.

【Original Information】

Integration of polygenic and gut metagenomic risk prediction for common diseases

2024-03-25, doi: 10.1038/s43587-024-00590-7

Li Xue + Deng Minzi et al.: Sitting for a long time can promote gastrointestinal diseases


(1) Xue Li from Zhejiang University and Minzi Deng from Central South University and their team published a study to explore the association between sedentary lifestyle and a variety of gastrointestinal diseases through Mendelian randomization (MR) analysis;(2) Longer leisure screen time (LST) was associated with an increased risk of various gastrointestinal diseases such as gastroesophageal reflux, gastric ulcer, duodenal ulcer, etc., and most of the associations persisted after adjusting for the genetic predisposition to moderate-to-vigorous physical activity (MVPA); (3) Individuals with a genetic predisposition to MVPA had gastroesophageal reflux, The risk of diseases such as gastric ulcer was reduced, and even after adjusting for LST, these associations were weakened but in the same direction;(4) Multivariate MR analysis showed that BMI and type 2 diabetes played a mediating role in the association between LST and MVPA and various gastrointestinal diseases.

【Original Information】

Sedentary lifestyle, physical activity, and gastrointestinal diseases: evidence from mendelian randomization analysis

2024-04 -06 , doi: 10.1016/j.ebiom.2024.105110

Biology of ferroptosis and its role in gastrointestinal diseases (review)


(1) Ferroptosis is a non-apoptotic, metabolically regulated form of cell death, which is caused by iron-dependent phospholipid peroxidation caused by the accumulation of reactive oxygen species (ROS), resulting in cell membrane damage and the release of damage-related molecular patterns, ferroptosis is related to aging and immunity, and has also been reported in the pathology of digestive tract diseases, but the specific molecular mechanism still needs to be proven, which is summarized and discussed in this review;(2) Ferroptosis is associated with intestinal diseases such as IBD, liver diseases including acute and chronic liver injury, viral hepatitis, Liver fibrosis and hemochromatosis, as well as cancers of the digestive tract, are closely related. (3) Unlike apoptosis, necroptosis, and pyroptosis, the regulatory mechanisms of ferroptosis are diverse and complex, with glutathione peroxidase 4 (GPX4) ferroptosis regulation being the classic ferroptosis control pathway.

【Original Information】

Ferroptosis: Biology and Role in Gastrointestinal Disease

2024-02-29 , doi: 10.1053/j.gastro.2024.01.051

Nature Reviews:FDA2023年批准的胃肠肝病新药一览

Nature Reviews Gastroenterology and Hepatology——[65.1]

(1) In 2023, the U.S. Food and Drug Administration's Center for Drug Evaluation and Research (CDER) approved 55 new drugs, four of which were associated with gastrointestinal and liver diseases, (2) and these newly approved drugs include Brenzavvy for improving glycemic control in patients with type 2 diabetes, Fruzaqla for refractory metastatic colorectal cancer (CRC), Omvoh and Velsipity for ulcerative colitis;(3) CDER has also expanded new uses for approved drugs, including Linzess for functional constipation in children, Lonsurf for previously treated metastatic colorectal cancer, Rinvoq as the first oral drug for Crohn's disease, and other drugs for the treatment of specific cancers in new pediatric populations; Entyvio for expanded injections, Hepzato for the treatment of liver metastases in selected patients with choroidal melanoma, and Zepbound for weight management.

【Original Information】

2023 FDA approvals in gastroenterology and hepatology

2024-03-07, doi: 10.1038/s41575-024-00916-1

Nature Reviews:Optimizing Antithrombotic Therapy in Patients with Cardiovascular and Gastrointestinal Diseases (Review)

Nature Reviews Cardiology——[49.6]

(1) emphasizing the importance of individualized treatment by comprehensively exploring optimal strategies for antithrombotic therapy in patients with cardiovascular disease and gastrointestinal complications; (2) various clinical conditions, including malabsorption syndrome, bariatric surgery, short bowel syndrome, or intestinal tube feeding, may affect the absorption and bioavailability of oral antithrombotic drugs;(3) The use of antithrombotic drugs in patients with high-risk gastrointestinal bleeding (GIB) is challenging, and most of the current models used to predict bleeding risk in patients with coronary artery disease do not specifically estimate the risk of GIB;(4) Identifying patients with high-risk GIB, modifying bleeding risk through the use of gastrointestinal protective agents, and determining appropriate antithrombotic regimens play a critical role in preventing GIB;(5) After an acute GIB episode, determining the duration of interruption of antithrombotic therapy and the regimen for restarting treatment needs to consider the balance between bleeding severity and risk of thrombotic events.

【Original Information】

Optimizing antithrombotic therapy in patients with coexisting cardiovascular and gastrointestinal disease

2024-03-20, doi: 10.1038/s41569-024-01003-3

Probiotics, a Singapore-based antimicrobial peptide company, has raised $6.2 million in Series A financing

(1) Recently, Probiotics, a Singapore-based antimicrobial peptide startup, announced that it has completed a Series A financing of US$6.2 million (about RMB 44.87 million); (2) This round of financing was led by Hatch's Blue Revolution Fund, with participation from Seventure Partners and SEEDS Capital; (3) Probiotics will use the funds to scale up production and develop lower-priced antimicrobial peptide products to move toward reducing the use of antibiotics in the food chain;(4) Probiotics is focused on biotechnology to develop industrially available and affordable antimicrobial peptide products, with its first product targeting the aquaculture industry, which is also the hardest hit by antibiotic abuse.

【Original Information】

Probiotics lands US$6.2M funding to cut antibiotics out of food supply chain

2024-04-09 , E27

Novo Nordisk oral bariatric therapy was declared for clinical trial in China

(1) On April 10, the clinical trial application submitted by Novo Nordisk's Class 1 new drug Amycretin, in China, was accepted by the Center for Drug Evaluation of the State Food and Drug Administration;(2) Amycretin, a long-acting dual agonist of oral GLP-1 receptor and amylin receptor, for the treatment of obesity;(3) In the phase 1 clinical trial, patients lost an average of 13.1% of body weight after 12 weeks of treatment with Amycretin, much higher than the 1.1% in the placebo group ;(4) Novo Nordisk plans to initiate a Phase 2 clinical trial in the second half of 2024 to evaluate the efficacy and safety of Amycretin in patients with type 2 diabetes.

【Original Information】

Lose more than 13% of your weight in 12 weeks! Novo Nordisk, an oral therapy, has been declared for clinical trial in China

2024-04-10 , Pharma Guanlan

Shandong New Era's "Capecitabine Tablets" was approved for marketing

(1) Recently, Shandong New Era Pharmaceutical's generic Class 4 drug capecitabine tablets have been approved for marketing by the State Drug Administration;(2) Capecitabine tablets are mainly used for the treatment of a variety of cancers, including colon cancer, breast cancer and gastric cancer; (3) The original drug capecitabine tablets were developed by Roche and approved in the United States in 1998 under the trade name Xeloda;(4) Six domestic companies have the production approval of capecitabine tablets, and all of them have passed the consistency evaluation;(5) In 2022, the sales scale of capecitabine tablets in China will exceed 1.5 billion yuan, and the main sales channel is the hospital market.

【Original Information】

1.5 billion antineoplastic drugs, Shandong New Era won!

2024-04-10, יהוה

Shanghai Pharmaceutical's rabeprazole sodium enteric-coated tablets passed the consistency evaluation of generic drugs

(1) On April 11, Shanghai Pharma announced that the rabeprazole sodium enteric-coated tablets of its Shanghai Pharmaceutical Xinyi Pharmaceutical Factory passed the consistency evaluation of generic drugs by the State Food and Drug Administration;(2) The drug is mainly used for the treatment of gastric ulcer, duodenal ulcer, anastomotic ulcer, reflux esophagitis, Zollinger-Ellison syndrome, and is used as an adjunct for the eradication of Helicobacter pylori in patients with gastric ulcer or duodenal ulcer;(3) (4) According to the QVIA database, the hospital procurement amount of the drug in 2023 will be RMB2.23 billion, and the main sales manufacturers include Jichuan Pharmaceutical, Eisai Pharmaceutical, and Chengdu Dikang Pharmaceutical.

【Original Information】

Shanghai Pharmaceutical: Announcement of Shanghai Pharmaceutical Group Co., Ltd. on Rabeprazole Sodium Enteric-coated Tablets Passing the Consistency Evaluation of Generic Drugs

2024-04-11 , Oriental Fortune Network

Puluo Pharmaceutical has joined hands with Heze Pharmaceutical to promote the pharmaceutical research and development of "semaglutide" and other drugs

(1) On April 9, Puluo Pharmaceutical and Heze Pharmaceutical signed a strategic cooperation agreement in Hengdian;(2) According to the agreement, the two parties will efficiently promote the pharmaceutical research and development of semaglutide injection, as well as the clinical efficacy and safety research of semaglutide in the treatment of type 2 diabetes and weight loss;(3) Puluo Pharmaceutical, founded in 1989, is a listed company on the main board of the Shenzhen Stock Exchange, and has an internationally leading production line and marketing team in the field of preparations;(4) Heze Pharmaceutical is a service-oriented platform company with drug R&D as the core, engaged in drug licensing and transformation, and is one of the largest professional, large-scale and comprehensive drug R&D institutions in China.

【Original Information】

Puluo Pharmaceutical has joined hands with Heze Pharmaceutical to promote pharmaceutical research and development such as semaglutide injection

2024-04-10 , Tentacle Creature


Click here to read the daily reports for the past 10 days:

0412 | The 10 articles focus on the new achievements of the domestic team, and the research on intestinal and microbiota has blossomed in many places

0411 | Nature Today: How do colon cells work with T cells to fight off bacterial infections?

0410 | 今日Cell:首个大规模泛癌转移瘤菌群图谱重磅出炉

0409 | 高分Nature子刊:菌群产物药物研发取得新进展

0408 | 3 Million People Data: What Does "Good" Cholesterol Associate with Digestive Tract Cancer Risk?

0407 | 100分综述详解:短链脂肪酸链起饮食、菌群和免疫

0406 | Jia Wei/Liu Tiemin/Zheng Xiaojiao Cell sub-journal new discovery: improve the intestinal bacteria metabolites of depression

0405 | Gaofen Cell Sub-journal: The team of China Agricultural University explains postbiotics in detail

0404 | The top journal has made new discoveries in the study of intestinal bacteria-related neurodevelopment and intestinal immunity

0403 | 今日Cell肠道研究双发:代谢胆固醇的肠菌+肠炎细胞图谱

Read on